Everything we do is to move us closer to our goal, of finding new treatments to slow, stop or reverse the progression of Parkinson’s. Your donations and your involvement in research will lead to the breakthrough we all want to see.
Curing Parkinson’s needs world-class collaborative science involving researchers, clinicians, the pharmaceutical industry and, most importantly, people who are living with Parkinson’s. This collaboration is at the heart of our research programme.
Our leadership and funding enables the world’s leading neuroscientists and neurologists to prioritise, together, the next generation of drugs for clinical trial. We’re acting with urgency, for people currently living with Parkinson’s, with a focus on research which has potential to translate into the clinic within five years.
In 2022, nearly 40% of all disease-modifying clinical trials currently happening have been previously assessed by Cure Parkinson’s International Linked Clinical Trials initiative (iLCT).
Out of 56 potentially disease-modifying treatments, only three were in the final phase 3 stage – one being the ‘Exenatide PD3 study’ supported by us. Importantly, Cure Parkinson’s is endeavouring to increase the number of clinical trials of disease-modifying treatments in phase 3 in the very near future, with the ambroxol phase 3 clinical trial due to start in mid-2023.
We’ve made significant progress towards our goal. As well as reshaping the approach to Parkinson’s research, we’ve directly funded, or secured funding, for over £75 million of clinical trials searching for a cure for Parkinson’s. But there’s so much more that we need to do.